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Abstract
Background: Sucrose density gradient centrifugation and cross-flow filtration methods have been
developed and standardised for the safe and reproducible production of inactivated arbovirus
antigens which are appropriate for use in diagnostic serological applications.
Methods: To optimise the maximum titre of growth during the propagation of arboviruses, the
multiplicity of infection and choice of cell line were investigated using stocks of Ross River virus and
Barmah Forest virus grown in both mosquito and mammalian cell lines. To standardise and improve
the efficacy of the inactivation of arboviral suspensions, stocks of Ross River virus, Barmah Forest
virus, Japanese encephalitis virus, Murray Valley encephalitis virus and Alfuy virus were chemically
inactivated using binary ethylenimine at a final concentration of 3 mM. Aliquots were then taken at
hourly intervals and crude inactivation rates were determined for each virus using a plaque assay.
To ensure complete inactivation, the same aliquots were each passaged 3 times in Aedes albopictus
C6/36 cells and the presence of viral growth was detected using an immunofluorescent assay. For
larger quantities of viral suspensions, centrifugation on an isopycnic sucrose density gradient or
cross-flow filtration was used to produce concentrated, pure antigens or partially concentrated,
semi-purified antigens respectively.
Results: The results of the propagation experiments suggested that the maximum viral titres
obtained for both Ross River virus and Barmah Forest virus were affected by the incubation period
and choice of cell line, rather than the use of different multiplicity of infection values. Results of the
binary ethylenimine inactivation trial suggested that standardised periods of 5 or 8 hours would be
suitable to ensure effective and complete inactivation for a number of different arboviral antigens.
Conclusion: Two methods used to prepare inactivated arbovirus antigens have been standardised
to minimise production failure and expenditure and to provide reagents that conform to the
highest quality and safety requirements of a diagnostic serology laboratory. The antigens are
suitable for use in either enzyme linked immunosorbent assays or haemagglutination inhibition
assays and the optimised protocols can be directly applied to produce antigens from new or
emerging arboviral pathogens.
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Background
Arthropod-borne viruses (arboviruses) may be transmit-
ted to man and other susceptible vertebrate hosts by
infected arthropods such as mosquitoes. There are over
100 arboviruses which are known to cause human infec-
tions with varying degrees of morbidity and mortality [1].
Included in the arbovirus group are single-stranded, posi-
tive sense RNA viruses belonging to the Alphavirus and Fla-
vivirus genera of the families Togaviridae and Flaviviridae
respectively [2]. In Australia, the alphaviruses that have
been implicated in human disease include Ross River
virus (RRV), Barmah Forest virus (BFV) and Sindbis virus,
whilst flaviviruses include Dengue virus serotypes 1-4
(DENV 1-4), Murray Valley encephalitis virus (MVEV),
Kunjin virus (KUNV), Japanese encephalitis virus (JEV)
and Kokobera virus. Additionally, antibodies which react
with 2 other flaviviruses namely, Alfuy virus (ALFV) and
Stratford virus, have also been found in human sera.
The serological diagnosis of arbovirus infections usually
involves the testing of paired acute and convalescent sera
in parallel, and requires stable, reliable antigens that are
reproducible and provide consistent results. The develop-
ment of standardised protocols to ensure the availability
of diagnostic antigens is an essential requirement in any
arboviral laboratory, and allows the testing of human and
animal sentinel surveillance sera for the diagnosis and
control of arboviral diseases. In addition, production of
antigens that are suitable for multiple serological assays
such as the enzyme linked immunosorbent assay (ELISA)
and the haemagglutination inhibition (HAI) assay,
improves the efficiency of the diagnostic laboratory and
increases the accuracy, reproducibility and reliability of
the results produced.
The production of antigens requires the propagation of
large quantities of high titre arboviral suspensions in cell
culture. Parameters such as choice of cell line, multiplicity
of infection (m.o.i.) and length of incubation period,
should be considered to obtain optimal viral growth. The
formation of nonviable deletion mutants or defective
interfering (DI) particles, a well known phenomenon
resulting from serial, high multiplicity passaging of many
viruses in cell culture, can interfere with the replication of
infectious virus and reduce yields [3-5]. To reduce the
effects of DI particle formation during the propagation of
virus, it may be useful to infect a particular cell line with a
stock virus previously grown in a different cell line.
Methods to produce antigens may vary depending upon
the amount and purity of antigen required and protocols
usually involve four steps: clarification by centrifugation,
inactivation, concentration and purification. Inactivation
of viruses during antigen production is not only essential
to prevent cross-contamination, but is also implemented
to minimise the exposure of personnel to biological haz-
ards and maintain a high standard of safe laboratory prac-
tices and procedures.
Binary ethylenimine (BEI) has been used to successfully
inactivate a number of RNA and DNA animal viruses for
antigen and vaccine production, including foot-and-
mouth disease virus [6], Rabies virus [7] and Newcastle
disease virus [8]. Although potentially carcinogenic, use of
a stock solution of 0.1 M BEI is far less toxic [9] and as a
chemical inactivant, may be more effective than other
means of inactivation such as ultraviolet radiation [10].
BEI is known to act on nucleic acid, with minimal effect
on the immunogenic properties of the viral protein coat.
In addition, we have chosen BEI inactivation as the rea-
gents required are inexpensive and the antigens produced
are highly stable [7].
Two methods for concentrating and purifying inactivated
arboviral antigens, namely, the sucrose density gradient
centrifugation (SDGC) method and the cross-flow filtra-
tion (CFF) method, were investigated. Viruses have been
purified previously by layering preparations on an isopyc-
nic (equilibrium) sucrose density gradient [11]. A similar
method using a potassium tartrate gradient has been used
to prepare a purified RRV antigen for use in an IgM ELISA
[12].
Cross-flow filtration technology has been utilized for
many applications including the purification of water [13]
and immunoglobulins [14]. In comparison to conven-
tional filtration methods, the use of CFF to concentrate
viral particles has several advantages. During CFF, culture
fluid is re-circulated in tangential flow, parallel to the filter
membrane. Build-up of viral particles on the membrane is
minimised by the recirculation of fluid over the surface,
which also facilitates the concentration of particles
present in the retentate fluid. In this way, alphavirus and
flavivirus particles may be partially concentrated and puri-
fied from culture fluids with the use of an appropriately
sized filter membrane.
The production of substantial quantities of good quality,
adequately concentrated antigens is crucial for the reliable
performance of diagnostic, serological assays. We describe
standardised, reproducible methods to produce safe, inac-
tivated arboviral antigens for use in serological tests using
either SDGC or CFF protocols. The methods described in
this paper produce inactivated reagents that can be used
immediately in a variety of ELISA and HAI assays, decreas-
ing hazardous risks to laboratory personnel and the
requirement of multiple protocols to produce different
antigens. In Australia, the application of these methods
for the production of antigens to exotic and emerging
arboviruses such as Chikungunya virus (CHIKV), WestBMC Microbiology 2004, 4 http://www.biomedcentral.com/1471-2180/4/3
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Nile virus (WNV) and Yellow fever virus (YFV), enables
the development of diagnostic assays for the future iden-
tification, management and control of outbreaks caused
by these pathogens.
Results
Optimal m.o.i. and choice of cell line
The haemagglutination (HA) titres (pH 5.8) obtained
from the optimal m.o.i. experiments using the RRV C6/36
stock were plotted against the hours of incubation for
each cell line infected (data not shown). Haemagglutina-
tion titres peaked by 47 hours post infection (Table 1).
The highest HA titre obtained was 8192, resulting from
the infection of Vero or BHK-21 C13 cells using m.o.i. val-
ues of approximately 8.0 × 10-2 to 2.0 × 10-4 plaque form-
ing units per cell (PFU/cell) and 8.0 × 10-2 to 2.0 × 10-3
PFU/cell respectively. In comparison, the maximum HA
titre that could be obtained from the infection of C6/36 or
a clone of porcine stable (PS-EK) cells [15] was 1024. HA
titres were not obtained from the negative control flasks.
Results from the BFV C6/36 stock optimum m.o.i. trials
demonstrated that viral HA titres (pH 5.8) peaked by 69
hours post infection (data not shown). The highest HA
titre that could be obtained from the infection of either
C6/36 or Vero cells, was 4096, using m.o.i. values of 1.5 ×
10-1 to 7.5 × 10-5 PFU/cell. The BH2193 strain of BFV used
could not be propagated in PS-EK cells.
BEI virus inactivation
The results of the alphavirus BEI inactivation trial using
the RRV and BFV C6/36 virus stocks are presented in Fig-
ure 1. The RRV C6/36 virus stock containing 2.0 × 107
plaque forming units per millilitre (PFU/mL) was inacti-
vated in 3 hours at 37°C, which can be expressed as an
inactivation rate of 2.4 Log10 PFU/mL of virus per hour
(Log10 PFU/mL.h-1). Similarly, the BFV C6/36 virus stock
containing 1.0 × 108 PFU/mL was inactivated in 4 hours at
37°C which produced an inactivation rate of 2.0 Log10
PFU/mL.h-1.
The results of the flavivirus BEI inactivation trial using the
JEV and MVEV C6/36 virus stocks and the ALFV PS-EK
virus stock are presented in Figure 2. A summary of the
results from both the alphavirus and flavivirus inactiva-
tion trials using a plaque assay are given in Table 2.
The time required for complete inactivation of the RRV
C6/36 virus stock samples was determined to be 3 hours
by plaque assay and 4 hours by immunofluorescent assay
(IFA) after serial passage in C6/36 cells. Similarly, the time
required to completely inactivate the JEV C6/36 and the
ALFV PS-EK virus stock samples was determined by serial
passage and IFA to be an hour longer than the time deter-
mined by plaque assay (data not shown). The time
required for complete inactivation of the DENV-1 C6/36
virus stock samples was determined by IFA to be 2 hours
following 3 passages in C6/36 cells.
Antigen production
Details of the inactivated arbovirus antigens made using
either the SDGC or CFF methods are listed in Table 3. The
inactivation times used were at least twice the number of
hours determined from the BEI inactivation trial experi-
ments. For the CHIKV antigen, 8 hours was used as the
inactivation time based on the results of the other alphavi-
ruses, RRV and BFV. For the flaviviruses WNV, JEV, MVEV,
KUNV, ALFV, YFV and DENV1-4, antigens were initally
inactivated for 5 hours based on the results from the
flavivirus inactivation trial. All antigens were successfully
inactivated, except DENV-2 and MVEV, for which the
inactivation time had to be increased to 8 hours. Com-
plete inactivation of all antigens was confirmed by IFA
and the absence of viral growth following serial passage in
C6/36 cells.
Table 1: Optimal m.o.i. values using RRV C6/36 stock virus with respective HA titre and hours of incubation in C6/36, PS-EK, Vero and 
BHK-21 C13 cell lines
Cell Line m.o.i. (PFU/cell) Maximum HA Titre at pH 5.8 Hours of Incubation
C6/36 1.5 × 10-4 1024 51
1.5 × 10-5 1024 51
PS-EK 1.1 × 10-1 1024 47
4.4 × 10-2 1024 47
2.2 × 10-2 1024 51
Vero 7.5 × 10-2 8192 47
3.0 × 10-2 8192 47
1.5 × 10-2 8192 47
1.5 × 10-3 8192 47
1.5 × 10-4 8192 47
BHK-21 C13 7.9 × 10-2 8192 51
3.2 × 10-2 8192 47
1.6 × 10-2 8192 47
1.6 × 10-3 8192 51BMC Microbiology 2004, 4 http://www.biomedcentral.com/1471-2180/4/3
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BEI inactivation of RRV and BFV C6/36 virus stocks at 37°C Figure 1
BEI inactivation of RRV and BFV C6/36 virus stocks at 37°C. The viral titres (Log10 PFU/mL) are shown decreasing with time 
(hours).
BEI inactivation of the JEV and MVEV C6/36 virus stocks and of the ALFV PS-EK virus stock at 37°C Figure 2
BEI inactivation of the JEV and MVEV C6/36 virus stocks and of the ALFV PS-EK virus stock at 37°C. The viral titres (Log10PFU/
mL) are shown decreasing with time (hours).
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Discussion
The optimisation of viral growth to obtain maximum viral
titres is necessary to produce high quality arboviral anti-
gens. In particular, our results suggested that the choice of
cell line may be more important than determining the
optimal m.o.i. when propagating arboviruses for antigen
production. Results of the optimal m.o.i. experiment
using RRV, demonstrated that at 47 hours post infection,
a maximum HA titre of 8192 could be produced in either
Vero or BHK-21 C13 vertebrate cells using the C6/36 virus
stock. This titre was obtained using several m.o.i. values
which varied as much as 2.0 Log10 PFU/cell. In contrast, a
lower maximum HA titre of 1024 resulted from the infec-
tion of PS-EK cells which was identical to the maximum
HA titre produced from the infection of C6/36 cells.
Although the use of C6/36 cells has been recommended
previously for the purpose of propagating RRV easily and
cheaply for use in antigen production [12], our results
suggested that RRV could be grown to a higher titre in
Vero or BHK-21 C13 cells efficiently with comparable
expense and use of resources.
In comparison, results from the optimal m.o.i. experi-
ment using BFV demonstrated that at 69 hours post
infection, virus could be grown to a maximum HA titre of
4096 by infecting either C6/36 or Vero cells with the C6/
36 virus stock. Similarly, several different m.o.i. values,
which varied as much as 5.0 Log10 PFU/cell, were used to
produce the same high HA titre. These results demon-
strated that for a given arbovirus stock, several m.o.i. val-
ues may be used to produce the same maximum HA titre,
provided the appropriate choice of cell line and incuba-
tion period is chosen. The use of higher virus dilutions
also did not improve the maximum virus HA titres of
8192 and 4096 obtained in the RRV and BFV m.o.i. exper-
iments respectively.
The results from the BEI inactivation experiments demon-
strated that the lowest BEI inactivation rates (Log10 PFU/
mL.h-1) were obtained for RRV and BFV alphavirus stocks,
whilst higher inactivation rates were obtained for JEV,
MVEV and ALFV flavivirus stocks. Factors affecting BEI
inactivation rates have been extensively discussed else-
where [6,9]. The inactivation rates were calculated using
the results from the plaque assays. Interestingly, when the
rates for the RRV, JEV and ALFV stocks were recalculated
based on the C6/36 cell culture results (data not shown),
higher inactivation rates were still achieved for the flaviv-
irus stocks, 2 of which had similar PFU/mL values to that
of the alphavirus stocks (Table 2). In addition to the deter-
mination of inactivation rates, we have also demonstrated
Table 2: Results of BEI alphavirus and flavivirus BEI inactivation trials at 37°C
Virus Stock Strain PFU/mL Hours for Complete BEI Inactivation Inactivation Rate (Log10 PFU/mL.h-1)
RRV C6/36 T48 2.0 × 107 32 . 4
BFV C6/36 BH2193 1.0 × 108 42 . 0
JEV C6/36 TS00 2.1 × 1011 11 1 . 3
MVEV C6/36 MRM66 2.5 × 108 24 . 2
ALFV PS-EK MRM3926 1.0 × 108 18 . 0
Table 3: Details of virus stocks, cell lines and BEI inactivated arbovirus antigens
Virus Stock Strain Cell Line Incubation (days/°C) HA upon Harvest (titre/pH) Inactivation Time (Hours) Antigen Method
RRV C6/36 T48 Vero 3/37 2048/5.8 8 CFF/SDGC
BFV C6/36 BH2193 Vero 3/37 2048/5.8 8 CFF/SDGC
CHIKV MBP BKM459 C6/36 2/28 1024/5.8 8 CFF
JEV PS-EK Nakayama PS-EK 3/37 2048/6.2 5 CFF/SDGC
KUNV C6/36 MRM16 PS-EK 3/37 1024/6.4 5 CFF
MVEV C6/36 MRM66 PS-EK 3/37 2048/6.4 8 CFF/SDGC
ALFV C6/36 MRM3926 PS-EK 3/37 512/6.4 5 CFF
DENV-1 C6/36 TIM00 C6/36 13/28 256/6.2 5 CFF
DENV-2 C6/36 TIM00 C6/36 8/28 256/6.2 8 CFF/SDGC
DENV-3 C6/36 TIM00 C6/36 7/28 512/6.2 5 CFF/SDGC
DENV-4 C6/36 TIM00 C6/36 11/28 256/6.2 5 CFF/SDGC
WNV C6/36 Sarafend PS-EK 2/37 1024/6.2 5 CFF
YFV C6/36 17D PS-EK 3/37 128/6.4 5 CFFBMC Microbiology 2004, 4 http://www.biomedcentral.com/1471-2180/4/3
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the ability to inactivate a range of both alphaviruses and
flaviviruses efficiently.
Effective virus inactivation methods should achieve the
irreversible loss of viral infectivity, with minimal loss of
antigenic properties [7,10]. Previous experiments have
suggested the use of 3 mM BEI and an incubation period
of 24 hours to inactivate a RRV Vero virus stock for vaccine
production [16]. However, in our experiments, 3 mM BEI
was used to inactivate more than 7.0 Log10 PFU/mL of a
RRV C6/36 virus stock in 4 hours. Although the results of
the IFA experiments following serial passage in C6/36
cells suggested 4 hours, we extended the BEI incubation
time to 8 hours and have been able to successfully make
safe and stable RRV antigens repeatedly. Indeed, passag-
ing 3 times in cell culture following inactivation was not
only found to be more sensitive than plaque assay for
detecting residual RRV, but also for detecting residual JEV
and ALFV.
Whilst BEI inactivation rates were determined for the
recent Australian JEV strain TS00 [17], we chose virus
stocks of the Nakayama vaccine strain of JEV as a safer
alternative for the production of large volumes of diag-
nostic antigen. The same propagation and inactivation
conditions used for the TS00 JEV strain were applied, and
the resulting Nakayama JEV strain antigen has been used
successfully in ELISA and HAI assays to detect seroconver-
sions in sentinel pigs [17-19].
We have now successfully produced arbovirus antigens
inactivated by 3 mM BEI using isopycnic SDGC or CFF
methods, including antigens of 3 viruses exotic to Aus-
tralia, namely, CHIKV, YFV and WNV. The Sarafend strain
of WNV was used to make an antigen as it was the only
strain initially available for this study. Recently, the NY99
strain of WNV has been obtained and a diagnostic antigen
using this strain will be produced. However it has been
shown previously that the amino acid homology between
the NY99 WNV and KUNV is 98–99% [20] and it is there-
fore possible that sera obtained from patients infected
with NY99 WNV, may demonstrate cross reactive antibod-
ies against the KUNV antigen.
Although the repeatability of inactivation rates was not
investigated, the inactivation period for the RRV, BFV, JEV,
MVEV and ALFV stocks was extended so that it became
least twice the time interval previously determined for
each virus. To provide a standardised protocol, 8 and 5
hours were determined to be adequate inactivation times
for alphaviruses and flaviviruses respectively. However in
comparison to other flaviviruses, when large volumes of
MVEV and DENV-2 antigens were produced, it became
necessary to extend the BEI incubation time from 5 to 8
hours to achieve complete inactivation. Further investiga-
tions of the pH and osmolarity of antigen suspensions,
which are known to affect the rate of BEI inactivation [9],
may provide a possible explanation for the difference
observed in inactivation rates. However, BEI inactivation
for 5 or 8 hours has proven repeatedly successful in the
inactivation of all the arbovirus antigens grown from the
virus stocks listed in Table 3 and provides a standardised
protocol for different virus cell culture preparations that
may vary significantly in HA titre. Furthermore, to ensure
complete inactivation, each antigen is routinely passaged
3 times in C6/36 cells to ensure complete inactivation.
Conclusions
The accurate and timely serological diagnosis of arboviral
infections requires the propagation, inactivation, purifica-
tion and concentration of suitable antigens that can be
produced efficiently, safely and reliably. We have demon-
strated that the inactivated arbovirus antigens produced
by SDGC or CFF protocols, are safe, high quality reagents
suitable for serological applications in the diagnostic lab-
oratory. The abilitity to use these antigens in more than
one serological assay has also enabled the screening of
human or sentinel animal sera against the same antigens.
This has improved the efficiency of diagnosis and accuracy
of results required for the identification, management and
control of outbreaks. In particular, seroconversions to JEV
and DENV infections during several recent outbreaks in
Australia, were detected using antigens that we have pro-
duced by these methods in ELISA and HAI assays [17-
19,21-23]. Furthermore, the availability of CHIKV and
YFV antigens may assist in the prevention of future out-
breaks of these exotic pathogens within Australia, whilst a
method to produce a safe NY99 WNV antigen would be of
particular importance to countries in North America cur-
rently experiencing outbreaks of this strain of WNV. The
establishment of improved, standardised methods for the
production of inactivated arbovirus antigens has also
reduced production failure and expenditure and signifi-
cantly decreased exposure of laboratory personnel to haz-
ardous reagents.
Methods
All centrifugation procedures were performed using a
Beckman Ultracentrifuge Optima L-80 (Beckman Instru-
ments, Inc., Fullerton, California) at 4°C.
Virus stocks
Viruses were propagated in C6/36 (American Type Cul-
ture Collection (ATCC) number CRL-1660), PS-EK cells,
Vero (ATCC number CCL-81) or BHK-21 C13  (ATCC
number CCL-10) cells (Table 3). Briefly, each virus was
diluted in a maintenance medium consisting of RPMI
1640 (CSL Limited, Parkville, VIC, Australia), 1% Hepes
(Gibco BRL® Invitrogen Pty, Ltd, Melbourne, VIC, Aus-
tralia) and 0.2% bovine serum albumin Fraction V (GibcoBMC Microbiology 2004, 4 http://www.biomedcentral.com/1471-2180/4/3
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BRL® Invitrogen Pty, Ltd, Melbourne, VIC, Australia). The
diluted virus was then used to inoculate confluent cell
monolayers grown in 10 × 180 cm2 flasks or 1 × expanded
surface 1700 cm2 roller bottle (Corning Costar Corpora-
tion, Cambridge, MA, USA). Following incubation for 1
hour at either 28°C (C6/36 cells) or 37°C (PS-EK, Vero or
BHK-21 C13 cells), cultures were re-fed with the same
maintenance medium (30 mLs per flask or 300 mLs per
roller bottle). After an appropriate incubation period, the
cell culture supernatant was harvested and the viral HA
titre was determined using a modification of the method
used by Clarke and Casals [24]. All subsequent virus dilu-
tions, inoculations and HA titre determinations were per-
formed under similar conditions.
Optimal m.o.i. and choice of cell line
The RRV C6/36 stock was used to investigate the optimal
m.o.i.and appropriate cell line required to obtain a maxi-
mum viral titre following inoculation. Briefly, confluent
monolayers of C6/36, PS-EK, Vero and BHK-21 C13 cells
(9.9 × 106, 6.6 × 106, 1.0 × 107 and 9.5 × 106 cells per 25
cm2 flask respectively) were infected with 6 dilutions of
virus. This resulted in m.o.i. values of 7.5 × 10-2 to 2.2 ×
10-5 PFU/cell. A negative control flask was also included in
each experiment. Following 22 hours post infection, an
aliquot of 50 µL of culture supernatant from each flask
was taken at appropriate intervals for the quantification of
HA titres at pH 5.8.
Similar experiments were also performed for the BFV C6/
36 stock, which was used to infect C6/36, Vero and PS-EK
cells with m.o.i. values of 4.0 × 10-1 to 8.0 × 10-5 PFU/cell.
BEI virus inactivation
To determine the appropriate time required to inactivate
RRV virus antigens with BEI, inactivation trials using the
RRV C6/36 virus stock were performed using a modifica-
tion of the method used by Larghi and Nebel [7] and 2-
bromoethylamine (Sigma Chemical Co., St. Louis, MO,
USA). Briefly, a 0.1 M BEI solution was prepared in 0.175
N sodium hydroxide, filtered through a 0.22 µm filter
(Millipore Corporation, Bedford, MA 01730, USA) and
incubated at 37°C in a waterbath for 30 minutes (final pH
8.5). An aliquot of 152 µL was added to 5 mLs of the virus
stock (final concentration of 3 mM BEI) and the virus sus-
pension was incubated at 37°C using a waterbath. Sam-
ples of 250 µL were taken at hourly intervals between 0
and 6 hours and also at 24 hours, before the inactivation
reaction was stopped with 25 µL of cold 1 M sodium thi-
osulphate. A modification of the method used by Gorman
and others was used to determine the PFU/mL of the orig-
inal virus stock and subsequent inactivated samples [15].
A carboxy-methyl cellulose overlay medium was used and
plaques were stained with naphthalene black [25]. An
aliquot of each inactivated sample was also passaged 3
times in C6/36 cells and the presence of any virus growth
was determined using a panel of monoclonal antibodies
in an IFA. Similarly, inactivation trials were also per-
formed for BFV, MVEV, JEV and ALFV virus stocks. The
DENV-1 C6/36 virus stock could not be plaqued, so inac-
tivation was only determined from the assessment of virus
viability by IFA after serial passage in C6/36 cells.
Viral antigen growth and antigen inactivation
Larger quantities of arboviruses were grown in cell culture
for antigen production, including 3 viruses exotic to Aus-
tralia, namely, CHIKV, WNV and YFV. For propagation of
viruses in C6/36 cells, 30 × 180 cm2 flasks (7.1 × 107 cells
and 3 mLs of inoculum per flask) were used, whilst for
viruses grown in Vero or PS-EK cells, 3 × 1700 cm2 roller
bottles (6.8 × 108 and 4.4 × 108 cells and 30 mLs of inoc-
ulum per bottle respectively) were used. The cell culture
supernatant (approximately 900 mLs) was harvested once
the HA titre had peaked, clarified by centrifugation at 10
000 × g for 30 minutes, and filtered through a sterile vac-
uum-driven 0.22 µm filter (Millipore Corporation, Bed-
ford, MA 01730, USA). A 0.1 M solution of BEI was
prepared as above in 27.3 mLs of 0.175 N sodium hydrox-
ide, and added to the filtered virus suspension.
Inactivation was performed for 5 or 8 hours, depending
on the determined optimal inactivation time, and the
reaction was stopped by addition of 90 mLs of cold 1 M
sodium thiosulphate. The inactivated virus suspension
was stored at 4°C overnight if antigen processing could
not be performed immediately.
Antigen production
Sucrose density gradient centrifugation
To pellet the virus, the inactivated virus suspension was
centrifuged at 10 000 × g for 17 hours overnight. A 5–50%
(w/v) isopycnic sucrose density gradient was made in a
Beckman 25 × 76 mm Ultraclear tube (Beckman Instru-
ments, Inc., Fullerton, California) using a modification of
the method described by Brakke [11]. Briefly, the virus
pellet was resuspended in 1 to 2 mLs of cold borate-saline
buffer pH 9.0 [24], carefully layered onto the sucrose
gradient and then centrifuged at 85 000 × g for 2 hours
and 30 minutes. The virus band was harvested using a
sterile Pasteur pipette, transferred to a Beckman 3 × 51
mm polyallomer tube (Beckman Instruments, Inc., Fuller-
ton, California) and diluted with cold borate-saline pH
9.0, almost filling the tube. The purified virus was col-
lected by centrifugation at 240 000 × g for 1 hour and 30
minutes, and the virus pellet was resuspended in 0.5 to
1.0 mL of cold borate-saline pH 9.0. Inactivation of the
concentrated purifed virus antigen was checked by filter-
ing a small aliquot (1:20 dilution) through a 0.22 µm fil-
ter and passaging 3 times in C6/36 cells as described
above. The viral antigen was stored at -80°C.BMC Microbiology 2004, 4 http://www.biomedcentral.com/1471-2180/4/3
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Antigen production
Cross-flow filtration
A CFF system consisting of a Satorius Sartocon Mini SM
17521 flow-distributing holding device, filter unit SM
3031466901E and peristaltic pump SM 16650 (Sartorius
AG, Goettingen, Germany) was used to prepare partially
concentrated, semi-purified viral antigens. Briefly, the BEI
inactivated viral suspension was recirculated parallel to
the filter unit (100,000 nomimal molecular weight cutoff)
in tangential flow with the aid of the peristaltic pump
under minimal pressure (<1 bar) until the volume of the
retentate was reduced to approximately 20 mLs. The inlet
tube was removed from the bottle containing the virus
suspension and the pumping resumed until as much of
the virus suspension as possible was recovered (approxi-
mately 100 mLs). This resulted in a ten-fold concentration
of the original virus suspension.
The pH of the virus antigen was adjusted to pH 9.0 by
addition of approximately 10 to 20 mLs of 0.25 M Tris-
HCl (pH 10.0). An aliquot was taken to determine the
post concentration HA titre and also to perform an inacti-
vation check as described for the SDGC antigen method.
The viral antigen was stored at -80°C.
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